Drug Target Review

JULY 4, 2023

2 However, when dosed at the MTD, ADCs display improved efficacy over small molecules in oncology trials. 3D rendering of Antibody Drug Conjugate Molecules. However, a more detailed look into the clinical data suggests that there is room for further dose optimisation, and this is exemplified by the small molecule drug Sotorasib.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Target Review

MARCH 15, 2024

About the author Dr Petra Dieterich, Senior Vice President at Abzena Petra has 30 years experience of in drug development in the pharmaceutical industry with a focus on supporting CMC activities. She has held leadership positions in Project Management, Technical Operations, and Business Development.

Organic Chemistry 59

Organic Chemistry Pharma Companies Clinical Trials Pharmaceuticals 59

Drug Target Review

MAY 1, 2024

At Zymeworks we apply a holistic approach to optimise each of the ADC components, leveraging insights gained from clinical trials and real-world clinical experience to inform the design of novel ADCs. Jamie Rich, PhD is Senior Director of Technology, ADC Therapeutic Development at Zymeworks Inc.

Drugs 69

Drugs FDA Approval Organic Chemistry Small Molecule 69